Address: At the Rare Hub, 1012 14th Street NW, Suite 500 Washington, DC 20005
Rare Disease Patients Need Access To Therapy Innovations
Thursday, February 25, 2021
By Michael Eging, Executive Director, RAAP One lesson we’ve learned from Covid-19 is that if innovative medical solutions, therapies and vaccines are available, accessible and affordable, then hundreds of millions of lives can be saved. At one point in our not too distant history, it would have been unthinkable that science would allow us to…
CMS APPROVAL OF TENNESSEE’S CLOSED FORMULARLY WAIVER WILL HURT RARE DISEASE PATIENTS
Thursday, January 14, 2021
CMS Granted Waiver is Duplicative, Costly and Steals Time From Those Without Time For Immediate Release January 13, 2021 Contact: Mike Eging 202-631-5752 [email protected] Washington, D.C. – On January 8th, CMS granted a waiver to the State of Tennessee that will allow Tennessee to exclude drugs from its Medicaid formulary but continue to…
Efforts to Cut Drug Prices Would Harm Rare-Disease Patients
Tuesday, February 25, 2020
Source: RealClear Politics By Michael Eging Government policy changes sometimes have all the subtlety of a steam roller, barreling forward without sufficient regard for everything in its path. Such is the case today with proposed changes to the Medicare prescription drug benefit (Part D), one of health care’s success stories. In an attempt to…
Rare Disease Drug Market May be Devastated by Current Proposed Changes to Medicare D, finds the Rare Access Action Project;
Tuesday, February 25, 2020
Study shows Cost Increases for Manufacturers could range from 400 percent to 2,000 percent “Unfortunately, these rather sweeping one-size-fits all plans could actually devastate the orphan drug market that serves patients who already have few options – if any,” said RAAP’s Mike Eging. WASHINGTON D.C. (02-25-2020) – The Rare Access Action Project (RAAP) announced results…
Changes in Medicare Part D Benefit Design Can Impact Availability of Future Treatments
Tuesday, February 25, 2020
With almost 50 million beneficiaries enrolled in the program, the Medicare prescription drug benefit (Part D) is considered by many to be a model of a successful government insurance program. Beneficiary premiums have declined 13.5% over the past 5 years, and most regions of the country have many prescription drug plan options for beneficiaries. Despite…
Medicare Part D
Thursday, October 31, 2019
Source: Washington Times A sledgehammer on a fragile market, when a scalpel is needed Making Changes to Medicare Part D that protect those with Rare Diseases By Michael Eging – Thursday, October 31, 2019 When is the last time anyone heard of a government program not only working well, but also coming in under…